

ICMJE DISCLOSURE FORM

Date: 6/22/2022
 Your Name: Kazuto Nishio
 Manuscript Title: Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)
 Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Eli Lilly and Company	Eli Lilly funded all support for the present manuscript
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Nippon Boehringer Ingelheim	
		West Japan Oncology Group	
		Thoracic Oncology Research Group	
		North East Japan Study Group	

		Clinical Research Support Center Kyushu	
		Eli Lilly Japan	
		Hitachi	
		SYSMEX	
		Nichirei Biosciences Inc.	
		Osakaminami hospital	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	SymBio Pharmaceuticals	
		Solasia Pharma	
		ELI LILLY JAPAN	
		Otsuka Pharmaceutical	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Boehringer Ingelheim Japan	honoraria for lectures
		AstraZeneca	honoraria for lectures
		Chugai	honoraria for lectures
		Novartis Pharma	honoraria for lectures
		Eisai	honoraria for lectures
		Bristol-Myers Squibb	honoraria for lectures
		MSD	honoraria for lectures
		Ono Pharmaceutical	honoraria for lectures
		Pfizer	honoraria for lectures
		Sanofi	honoraria for lectures
		Guardant Health	honoraria for lectures
		ELI LILLY JAPAN.	honoraria for lectures
		Amgen	honoraria for lectures
		Merck Biopharma	honoraria for lectures
		Roche Diagnostics	honoraria for lectures
		Yakult Honsha	honoraria for lectures
		Takeda pharmaceuticals	honoraria for lectures
		FUJIREBIO	honoraria for lectures
		Janssen Pharmaceutical	honoraria for lectures
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society,	<input checked="" type="checkbox"/> None	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

The author reports the funding from Eli Lilly and Company, grants or contracts from Eli Lilly Japan, Clinical Research Support Center Kyushu, Hitachi, Nichirei Biosciences, Nippon Boehringer Ingelheim, North East Japan Study Group, Osakaminami Hospital, Sysmex Corporation, Thoracic Oncology Research Group, and West Japan Oncology Group; consulting fees from Eli Lilly Japan, Otsuka Pharmaceutical, Solasia Pharma, and SymBio Pharmaceuticals; and honoraria for lectures from Amgen, AstraZeneca, Boehringer Ingelheim Japan, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly Japan, Fujirebio, Guardant Health, Janssen, Merck Biopharma, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, Roche Diagnostics, Sanofi, Takeda, and Yakult Honsha.

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 6/22/2022

Your Name: Kazuko Sakai

Manuscript Title: Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Eli Lilly and Company	Eli Lilly funded all support for the present manuscript
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

The author reports the funding from Eli Lilly and Company.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 7/19/2022
 Your Name: Makoto Nishio
 Manuscript Title: Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)
 Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Eli Lilly and Company	Eli Lilly funded all support for the present manuscript
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

The author reports the funding from Eli Lilly and Company.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 7/19/2022

Your Name: Takashi Seto

Manuscript Title: Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Eli Lilly and Company	Eli Lilly funded all support for the present manuscript
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Abbvie	My Institution
		Chugai Pharmaceutical	My Institution
		Daiichi Sankyo	My Institution
		Eli Lilly Japan	My Institution
		Kissei Pharmaceutical	My Institution
		MSD	My Institution
		Novartis Pharma	My Institution
		Pfizer Japan	My Institution

		Takeda Pharmaceutical	My Institution
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	AstraZeneca	honoraria for lectures
		Bristol-Myers Squibb	honoraria for lectures
		Chugai Pharmaceutical	honoraria for lectures
		Covidien Japan	honoraria for lectures
		Daichi Sankyo	honoraria for lectures
		Eli Lilly Japan	honoraria for lectures
		Kyowa Hakko Kirin	honoraria for lectures
		MSD	honoraria for lectures
		Mochida Pharmaceutical	honoraria for lectures
		Nippon Boehringer Ingelheim	honoraria for lectures
		Novartis Pharma	honoraria for lectures
		Ono Pharmaceutical	honoraria for lectures
		Pfizer Japan	honoraria for lectures
		Taiho Pharmaceutical	honoraria for lectures
		Takeda Pharmaceutical	honoraria for lectures
Towa Pharmaceutical	honoraria for lectures		
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	

13	Other financial or non-financial interests	Precision Medicine Asia	employment

Please summarize the above conflict of interest in the following box:

The author reports the funding from Eli Lilly and Company and grants or contracts to their institution from AbbVie, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Kissei Pharmaceutical, Merck Sharp & Dohme, Novartis, Pfizer Japan, and Takeda Pharmaceutical; honoraria for lectures from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Covidien Japan, Daiichi Sankyo, Eli Lilly Japan, Kyowa Hakko Kirin, Merck Sharp & Dohme, Mochida Pharmaceutical, Nippon Boehringer Ingelheim, Novartis, Ono Pharmaceutical, Pfizer Japan, Taiho Pharmaceutical, Takeda, and Towa Pharmaceutical; and employment with Precision Medicine Asia.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 9/15/2021

Your Name: Carla Visseren-Grul

Manuscript Title: Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Eli Lilly and Company	Eli Lilly funded all support for the present manuscript
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	I am an Eli Lilly employee	I am an Eli Lilly employee and as such hold Lilly stock
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

The author reports the funding from Eli Lilly and Company. The author is also an Eli Lilly employee and as such hold Lilly stock.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 7/20/2022

Your Name: Michelle Carlsen

Manuscript Title: Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Eli Lilly and Company	Eli Lilly funded all support for the present manuscript
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	Stock of Eli Lilly and Company	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	Employee of Eli Lilly and Company	

Please summarize the above conflict of interest in the following box:

The author reports the funding from Eli Lilly and Company. The author is also an employee and minor shareholder of Eli Lilly and Company.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: :7/20/2022

Your Name: Tomoko Matsui

Manuscript Title: Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Eli Lilly and Company	Eli Lilly funded all support for the present manuscript
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

The author reports the funding from Eli Lilly and Company. The author is also an employee of Eli Lilly Japan K.K. and is minor shareholder of Eli Lilly and Company.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 7/20/2022

Your Name: Sotaro Enatsu

Manuscript Title: Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Eli Lilly and Company	Eli Lilly funded all support for the present manuscript
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	Stock of Eli Lilly and Company	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	Employee of Eli Lilly Japan	

Please summarize the above conflict of interest in the following box:

The author reports the funding from Eli Lilly and Company. The author is also an employee of Eli Lilly Japan K.K. and is minor shareholder of Eli Lilly and Company.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 8/9/2022

Your Name: Kazuhiko NAKAGAWA

Manuscript Title: Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Eli Lilly and Company	Eli Lilly funded all support for the present manuscript
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	AstraZeneca K.K.	My institution
		MSD K.K.	My institution
		Ono Pharmaceutical Co.,Ltd.	My institution
		Nippon Boehringer Ingelheim Co.,Ltd.	My institution
		Novartis Pharma K.K.	My institution
		Pfizer Japan Inc.	My institution

		Bristol Myers Squibb Company	My institution
		Eli Lilly Japan K.K.	My institution
		Chugai Pharmaceutical Co.,Ltd.	My institution
		Daiichi Sankyo Co., Ltd.	My institution
		Merck Biopharma	My institution
		PAREXEL International Corp.	My institution
		PRA HEALTHSCIENCES	My institution
		EPS Corporation.	My institution
		Kissei Pharmaceutical Co., Ltd.	My institution
		EPS International Co.,Ltd,.	My institution
		Taiho Pharmaceutical Co.,Ltd.	My institution
		PPD-SNBL K.K	My institution
		SymBio Pharmaceuticals Limited.	My institution
		IQVIA Services JAPAN K.K.	My institution
		SYNEOS HEALTH CLINICAL K.K.	My institution
		Nippon Kayaku Co.,Ltd.	My institution
		EP-CRSU Co., Ltd.	My institution
		Mebix, Inc.	My institution
		Janssen Pharmaceutical K.K.	My institution
		AbbVie Inc.	My institution
		Bayer Yakuhin, Ltd	My institution
		Eisai Co., Ltd.	My institution
		Mochida Pharmaceutical Co., Ltd.	My institution
		Covance Japan Inc.	My institution
		Japan Clinical Research Operations	My institution
		Takeda Pharmaceutical Co.,Ltd.	My institution
		GlaxoSmithKline K.K.	My institution
		Sanofi K.K.	My institution
		Systemex Corporation	My institution
		Medical Reserch Support	My institution
		Otsuka Pharmaceutical Co., Ltd.	My institution
		SRL, Inc.	My institution
		Pfizer R&D Japan G.K.	My institution
		Amgen Inc.	My institution
3	Royalties or licenses	<input type="checkbox"/> None	
4	Consulting fees	Eli Lilly Japan K.K.	Myself
		KYORIN Pharmaceutical	Myself

		Co., Ltd.	
		Ono Pharmaceutical Co.,Ltd.	Myself
		Pfizer Japan Inc.	Myself
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Ono Pharmaceutical Co., Ltd.	Myself
		Amgen Inc.	Myself
		Nippon Kayaku Co., Ltd.	Myself
		AstraZeneca K.K.	Myself
		Chugai Pharmaceutical Co., Ltd.	Myself
		Eli Lilly Japan K.K.	Myself
		MSD K.K.	Myself
		Pfizer Japan Inc.	Myself
		Nippon Boehringer Ingelheim Co., Ltd.	Myself
		Taiho Pharmaceutical Co.,Ltd.	Myself
		Bayer Yakuhin, Ltd.	Myself
		CMIC ShiftZero K.K.	Myself
		Life Technologies Japan Ltd.	Myself
		Neo Communication	Myself
		Roche Diagnostics K.K.	Myself
		AbbVie Inc.	Myself
		Merck Biopharma Co., Ltd.	Myself
		Kyowa Kirin Co., Ltd.	Myself
		Takeda Pharmaceutical Co., Ltd.	Myself
		3H Clinical Trial Inc.	Myself
		Care Net, Inc.	Myself
		Medical Review Co., Ltd.	Myself
		Medical Mobile Communications co., Ltd	Myself
		YODOSHA CO., LTD.	Myself
		Nikkei Business Publications, Inc.	Myself
		Japan Clinical Research Operations	Myself
		Novartis Pharma K.K.	Myself
		CMIC Co., Ltd.	Myself
		TAIYO Pharma Co., Ltd.	Myself
		KYORIN Pharmaceutical Co., Ltd.	Myself
		Bristol-Myers Squibb K.K.	Myself
6	Payment for expert testimony	<input type="checkbox"/> None	
7	Support for attending	<input type="checkbox"/> None	

	meetings and/or travel		
8	Patents planned, issued or pending	Daiichi Sankyo Co., Ltd.	My institution
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

The author reports the funding from Eli Lilly and Company and grants or contracts to their institution from AbbVie, Amgen, AstraZeneca K.K., Bayer Yakuhin, Bristol Myers Squibb, Chugai Pharmaceutical, Covance Japan, Daiichi Sankyo, Eisai, Eli Lilly Japan K.K., EP-CRSU, EPS Corporation, EPS International, GlaxoSmithKline K.K., IQVIA Services Japan K.K., Janssen Pharmaceutical K.K., Japan Clinical Research Operations, Kissei Pharmaceutical, Mebix, Medical Research Support, Merck Biopharma, Merck Sharp & Dohme K.K., Mochida Pharmaceutical, Nippon Boehringer Ingelheim, Nippon Kayaku, Novartis Pharma K.K., Ono Pharmaceutical, Otsuka Pharmaceutical, Parexel, Pfizer Japan, Pfizer R&D Japan G.K., PPD-SNBL K.K., PRA Health Sciences, Sanofi K.K., SRL, Symbio Pharmaceuticals, Syneos Health Clinical K.K., Sysmex Corporation, Taiho Pharmaceutical, and Takeda; consulting fees from Eli Lilly Japan K.K., KYORIN Pharmaceutical, Ono Pharmaceutical, and Pfizer Japan; payment or honoraria from 3H Clinical Trial, AbbVie, Amgen, AstraZeneca K.K., Bayer Yakuhin, Bristol Myers Squibb K.K., Care Net, Chugai Pharmaceutical, CMIC, CMIC ShiftZero K.K., Eli Lilly Japan K.K., Japan Clinical Research Operations, KYORIN Pharmaceutical, Kyowa Kirin, Life Technologies Japan, Medical Mobile Communications, Medical Review, Merck Serono, Merck Sharp & Dohme K.K., Neo Communications, Nikkei Business Publications, Nippon Boehringer Ingelheim, Nippon Kayaku, Novartis Pharma K.K., Ono Pharmaceutical, Pfizer Japan, Roche Diagnostics K.K., Taiho Pharmaceutical, TAIYO Pharma, Takeda Pharmaceutical, and YODOSHA; and patents planned, issued, or pending with Daiichi Sankyo and their institution.

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.